Vagus Nerve Stimulation (VNS) trial seeks to mitigate dangerous immune response.
OVERLAND PARK, KS, May 22, 2020 /24-7PressRelease/ — Dr. Patrick Nemechek, founder of Nemechek Technologies, registered a study with ClinicalTrials.Gov to determine the therapeutic effect of transcutaneous vagus nerve stimulation (tVNS) in patients with moderate, severe, or critical pneumonia associated with COVID-19.
Patients hospitalized with COVID-19 are dying of acute respiratory distress syndrome (ARDS) due to a surge of pro-inflammatory cytokines. ARDS is the reason such a high percentage of patients require mechanical ventilation. Watch the brief YouTube video.
Known as a cytokine storm, the surge of inflammatory molecules is a life-threatening reaction similar to septic shock. A proposed therapy to mitigate the cytokine storm is electrical stimulation of the vagus nerve. Known as the Inflammatory Reflex, stimulating the vagus nerve with a mild electrical current may enable physicians to defeat the dangerous and deadly cytokine storm.
Nemechek Technologies proposes to use its Vitality Smartcable tVNS device to suppress pro-inflammatory cytokines and improve COVID-19 patient outcomes. Bioelectrical stimulation of the vagus nerve may fill the urgent need for improving a patient’s immune regulation. Dr. Nemechek will donate devices for use in this study to evaluate how effective tVNS is in decreasing ICU admissions, patient intubations, and mortality.
“The Vitality Smartcable is safe, portable, inexpensive, and doesn’t interfere with other therapies. Importantly, a single device can be shared among many patients with minimum sterilization. We hope to demonstrate tVNS is a potentially life-saving COVID-19 therapy that can be available to resource-limited countries around the world.” – Patrick Nemechek, D.O.
Nemechek Technologies, LLC is a privately held company that produces and markets the Vitality Smartcable, the only neuromodulator powered by your smartphone. The Vitality Smartcable is designed to meet the FDA’s General Wellness Policy for Low-Risk Devices as a self-administered neuromodulation device to maintain optimal health.
Dr. Nemechek was awarded U.S. Patent No. 10,335,396 for his method of using VNS to lower inflammation. He also developed The Nemechek Protocol®, which uses VNS to reduce inflammation and has treated more than 1,000 patients with VNS therapy at his Phoenix-area clinic.
See Dr. Nemechek’s LinkedIn profile for more information on his extensive research and clinical experience.
Nemechek Technologies, LLC
For the original version of this press release, please visit 24-7PressRelease.com here